Production and characterization of virus-like particles of grapevine fanleaf virus presenting L2 epitope of human papillomavirus minor capsid protein.


Journal

BMC biotechnology
ISSN: 1472-6750
Titre abrégé: BMC Biotechnol
Pays: England
ID NLM: 101088663

Informations de publication

Date de publication:
21 11 2019
Historique:
received: 12 07 2019
accepted: 09 10 2019
entrez: 23 11 2019
pubmed: 23 11 2019
medline: 9 4 2020
Statut: epublish

Résumé

Virus-like particle (VLP) platform represents a promising approach for the generation of efficient and immunogenic subunit vaccines. Here, the feasibility of using grapevine fanleaf virus (GFLV) VLPs as a new carrier for the presentation of human papillomavirus (HPV) L2 epitope was studied. To achieve this goal, a model of the HPV L2 epitope secondary structure was predicted and its insertion within 5 external loops in the GFLV capsid protein (CP) was evaluated. The epitope sequence was genetically inserted in the αB-αB The results demonstrate that GFLV VLPs constitute a potential scaffold for surface display of the epitope of interest.

Sections du résumé

BACKGROUND
Virus-like particle (VLP) platform represents a promising approach for the generation of efficient and immunogenic subunit vaccines. Here, the feasibility of using grapevine fanleaf virus (GFLV) VLPs as a new carrier for the presentation of human papillomavirus (HPV) L2 epitope was studied. To achieve this goal, a model of the HPV L2 epitope secondary structure was predicted and its insertion within 5 external loops in the GFLV capsid protein (CP) was evaluated.
RESULTS
The epitope sequence was genetically inserted in the αB-αB
CONCLUSIONS
The results demonstrate that GFLV VLPs constitute a potential scaffold for surface display of the epitope of interest.

Identifiants

pubmed: 31752839
doi: 10.1186/s12896-019-0566-y
pii: 10.1186/s12896-019-0566-y
pmc: PMC6868843
doi:

Substances chimiques

Capsid Proteins 0
Epitopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Références

J Virol. 2010 Aug;84(16):7924-33
pubmed: 20519403
J Gen Virol. 2004 Apr;85(Pt 4):1049-53
pubmed: 15039547
Curr Opin Biotechnol. 2011 Dec;22(6):901-8
pubmed: 21592772
J Biosci. 2012 Mar;37(1):125-33
pubmed: 22357210
PLoS Pathog. 2011 May;7(5):e1002034
pubmed: 21625570
Curr Opin Virol. 2016 Jun;18:44-9
pubmed: 27039982
Virology. 2007 Jun 20;363(1):59-68
pubmed: 17320136
PLoS One. 2012;7(11):e49751
pubmed: 23185426
Front Plant Sci. 2015 Dec 24;6:1138
pubmed: 26734041
Vaccine. 2006 Sep 29;24(40-41):6414-23
pubmed: 16860441
Biotechnol Bioeng. 2014 Mar;111(3):425-40
pubmed: 24347238
Curr Opin Biotechnol. 2016 Feb;37:201-206
pubmed: 26773389
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
Arch Virol. 2004 Jan;149(1):137-54
pubmed: 14689280
Vaccine. 2001 Feb 8;19(13-14):1783-93
pubmed: 11166904
Vaccine. 1995 Aug;13(12):1051-7
pubmed: 7491811
Naturwissenschaften. 2005 Feb;92(2):51-64
pubmed: 15558225
Nat Commun. 2018 Jun 18;9(1):2369
pubmed: 29915210
Immunol Cell Biol. 2005 Jun;83(3):263-70
pubmed: 15877604
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Mar-Apr;3(2):174-196
pubmed: 20872839
Vaccine. 2007 Jun 15;25(25):4784-94
pubmed: 17499404
J Virol. 2008 Jan;82(2):785-94
pubmed: 17989184
Plant Biotechnol J. 2016 Dec;14(12):2288-2299
pubmed: 27178344
Viruses. 2017 Nov 10;9(11):
pubmed: 29125554
Adv Protein Chem. 2003;64:1-36
pubmed: 13677044
J Virol. 1997 Oct;71(10):7781-90
pubmed: 9311863
Vaccine. 2001 May 14;19(25-26):3376-83
pubmed: 11348701
Curr Opin Struct Biol. 1996 Apr;6(2):176-82
pubmed: 8728650
Rep Biochem Mol Biol. 2015 Oct;4(1):19-24
pubmed: 26989746
Chem Commun (Camb). 2017 Jul 4;53(54):7632-7634
pubmed: 28640305
Vaccine. 2010 Jun 17;28(27):4384-93
pubmed: 20434554
Virology. 2005 Dec 20;343(2):224-35
pubmed: 16185741
Virology. 2009 Oct 25;393(2):329-37
pubmed: 19733890
PLoS One. 2017 Jan 5;12(1):e0169533
pubmed: 28056100
Int J Nanomedicine. 2007;2(4):715-33
pubmed: 18203438
Virology. 2009 May 25;388(1):185-90
pubmed: 19344926
J Biotechnol. 2007 Feb 1;128(2):290-6
pubmed: 17113675
Hum Vaccin Immunother. 2013 Jan;9(1):26-49
pubmed: 22995837
Vaccine. 2001 Jun 14;19(27):3661-70
pubmed: 11395200
Oncotarget. 2015 Apr 30;6(12):10253-66
pubmed: 25860935
Talanta. 2017 Dec 1;175:325-330
pubmed: 28841998
Nat Biotechnol. 2006 Nov;24(11):1377-83
pubmed: 17093488
Vaccine. 2018 Jul 16;36(30):4462-4470
pubmed: 29914845
Adv Drug Deliv Rev. 2012 Jun 15;64(9):811-25
pubmed: 22285585
Anal Chem. 2001 Aug 15;73(16):3900-6
pubmed: 11534714
BMC Biotechnol. 2015 Aug 27;15:80
pubmed: 26311254
Vaccine. 2002 Aug 19;20(25-26):3155-64
pubmed: 12163267
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Immunology. 1992 Oct;77(2):262-6
pubmed: 1385315
PLoS One. 2011;6(8):e23310
pubmed: 21858066
Electrophoresis. 2005 Aug;26(16):3105-12
pubmed: 16047314
Biomacromolecules. 2003 May-Jun;4(3):472-6
pubmed: 12741758

Auteurs

Razieh Yazdani (R)

Plant Pathology Department, Faculty of Agriculture, Tarbiat Modares University, Pajouhesh Blvd., Tehran to Karaj highway, Tehran, Iran.
Laboratory for the Analysis of Medicines (LAM), Department of Pharmaceutical Sciences, CIRM, University of Liège, Quartier Hôpital, B36, Tower 4, Avenue Hippocrate, 15, 4000, Liège, Belgium.

Masoud Shams-Bakhsh (M)

Plant Pathology Department, Faculty of Agriculture, Tarbiat Modares University, Pajouhesh Blvd., Tehran to Karaj highway, Tehran, Iran. shamsbakhsh@modares.ac.ir.

Afshin Hassani-Mehraban (A)

TAK Inspection Co, Karegar Ave, Tehran, 346, Iran.

Seyed Shahriar Arab (SS)

Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Nicolas Thelen (N)

Cellular and Tissular Biology, GIGA-Neurosciences, University of Liège, Liège, Belgium.

Marc Thiry (M)

Cellular and Tissular Biology, GIGA-Neurosciences, University of Liège, Liège, Belgium.

Jacques Crommen (J)

Laboratory for the Analysis of Medicines (LAM), Department of Pharmaceutical Sciences, CIRM, University of Liège, Quartier Hôpital, B36, Tower 4, Avenue Hippocrate, 15, 4000, Liège, Belgium.

Marianne Fillet (M)

Laboratory for the Analysis of Medicines (LAM), Department of Pharmaceutical Sciences, CIRM, University of Liège, Quartier Hôpital, B36, Tower 4, Avenue Hippocrate, 15, 4000, Liège, Belgium.

Nathalie Jacobs (N)

Cellular and Molecular Immunology, GIGA-Research, University of Liège, Liège, Belgium.

Alain Brans (A)

Center for Protein Engineering, University of Liège, Chemistry Institute B6, 4000, Liège (Sart Tilman), Belgium.

Anne-Catherine Servais (AC)

Laboratory for the Analysis of Medicines (LAM), Department of Pharmaceutical Sciences, CIRM, University of Liège, Quartier Hôpital, B36, Tower 4, Avenue Hippocrate, 15, 4000, Liège, Belgium. acservais@uliege.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH